Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesLongevityLivagen

Livagen

/ Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Ala); proposed liver bioregulator
SPECULATIVEN = 0 · TESTING PENDING

ALIAS · KEDA · Lys-Glu-Asp-Ala · Liver peptide bioregulator

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequenceKEDA
MW · CLASS · Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Ala); proposed liver bioregulatorCATEGORY · Longevity

Tier 4. Khavinson-tradition tetrapeptide Lys-Glu-Asp-Ala (KEDA) marketed as a liver bioregulator. PubMed-indexed primary literature is sparse and concentrates on chromatin-decondensation and lymphocyte-related effects from the Khavinson group; the claim of tissue-specific liver regulation rests on class-level reviews rather than independent organ-specific work.

§ B · Mechanism of action

Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA). Within the Khavinson-tradition framework the proposed mechanism is direct interaction with chromatin and promoter regions, with reported in-vitro effects on chromatin decondensation in lymphocytes and modulation of cytokine expression. The tissue-specific liver regulation claim is asserted by analogy to the broader tissue-specific peptide framework rather than from organ-targeted experimental work.

§ C · Human clinical evidence

Tier 4. The available PubMed-indexed primary literature is in-vitro and from the Khavinson group, principally on lymphocyte chromatin and cytokine effects. No human clinical-trial data.

§ F · Safety signal

No formal human safety database. General Khavinson-tradition short-peptide class concerns (identity, purity, vendor manufacturing) apply.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.

The disconnect between published Livagen primary literature (lymphocyte chromatin / cytokine in vitro) and vendor marketing (liver tissue regulation) is not bridged by published organ-specific experimental data.